Homepage > Rare diseases > Search

Search for a rare disease

*
(*) mandatory field

Recessive X-linked ichthyosis

Suggest an update
Your message has been sent Your message has not been sent. Please contact an administrator.
Disease definition

A rare genetic skin disease belonging to the Mendelian Disorders of Cornification (MeDOC) and characterized by generalized hyperkeratosis and scaling of the skin. The condition is rather mild.

ORPHA:461

Classification level: Disorder

Synonym(s):
  • RXLI
  • Steroid sulfatase deficiency
  • X-linked ichthyosis
  • XLI

Source: PubMed ID 11850936 28846233 30318799

Prevalence: 1-5 / 10 000

Inheritance: X-linked recessive

Age of onset: Neonatal

ICD-10: Q80.1

ICD-11: EC20.01

OMIM: 308100

UMLS: C2720163

MeSH: D016114

GARD: 7904

Summary
Epidemiology

RXLI affects almost exclusively males. It is the second most common type of ichthyosis with an estimated prevalence of 1/2,000 to 1/6,000 males.

Clinical description

Onset may occur within the first days of life with the development of generalized non-erythematous, polygonal, loosely adherent scales. These scales later evolve into grayish or blackish adherent scales that are pronounced on the trunk, the extensor and flexor sites of the extremities, and the neck (giving the ''dirty-neck'' appearance). Skin's folds, palms and soles, are normally spared. Scaling improves with age and during summer. Delayed birth (insufficient cervical dilatation) may be observed. Extracutaneous manifestations like testicular maldescent, attention deficit and hyperactivity disorder (ADHD) and/or corneal opacities are possible. Large deletions involving adjacent genes may result in more complex phenotypes (contiguous gene deletion syndromes like Kallman´s syndrome, the recessive form of X-linked chondrodysplasia punctata, short stature, intellectual disability, or central nervous systems anomalies).

Etiology

X-linked ichthyosis is an epidermal lipid metabolism anomaly due to inactivating mutations or deletions in the steroid sulfatase STS gene (Xp22.3). STS codes for a lipid hydrolase of the stratum corneum that participates in the regulation of permeability, barrier homeostasis and desquamation by catalyzing the hydrolysis of steroid sulfates (e.g. cholesterol sulfate CSO4, sulfated steroid hormones). STS deficiency leads to increased amounts of CSO4 that inhibit epidermal serine proteases, which in turn results in decreased desquamation of corneocytes with retention hyperkeratosis. There are some much rarer syndromic RXLI cases that are due to contiguous gene deletion affecting neighboring genes of the STS gene.

Diagnostic methods

Diagnosis is based on clinical findings and family history (scaling in male relatives, history of delayed birth). It is confirmed by biochemical (serum protein electrophoresis, STS activity test of fibroblasts or leukocytes) and molecular/cytogenetic analyses (polymerase chain reaction (PCR), multiple ligation-dependent probe amplification (MLPA), comparative genomic hybridization/comparative microarray analysis (CMA), fluorescent in situ hybridization (FISH)). Histology or ultrastructure of the skin is helpful for the differentiation of ichthyosis vulgaris.

Differential diagnosis

Differential diagnosis includes ichthyosis vulgaris, autosomal recessive congenital ichthyosis (ARCI), namely lamellar ichthyosis, syndromic RLXI, or multiple sulfatase deficiency.

Antenatal diagnosis

Maternal urine and serum steroid measurements may show decreased estrogen levels. Therefore, RXLI may be detected in utero, when maternal estriol levels are measured for prenatal screening for Down syndrome and other disorders.

Genetic counseling

XLRI is transmitted as an X-linked recessive trait: it affects males and is inherited through female carriers. Female patients have rarely been reported.

Management and treatment

Treatment consists in hydrating and softening the skin with the use of lubricating bath oils and emollients containing humectants and keratolytics (e. g. urea, lactic acid, and glycolic acid). For adult patients, systemic retinoids are an option, e. g. during winter, when the ichthyosis is often more severe.

Prognosis

RXLI represents a benign form of ichthyosis. The ichthyosis is life-long but hyperkeratosis and scaling may improve with age. Life expectancy is normal.

Last update: December 2022 - Expert reviewer(s): Dr Ángela HERNÁNDEZ MARTÍN
Detailed information

Logo ERN: produced/endorsed by ERN(s) Logo FSMR: produced/endorsed by FSMR(s)

Guidelines
Emergency guidelines
Français (2018.pdf) - Orphanet Urgences
Clinical practice guidelines
English (2018) - Br J Dermatol Logo ERN
English (2019) - Br J Dermatol Logo ERN
Disease review articles
Clinical genetics review
English (2013.pdf) - Eur J Hum Genet
Patient-Centered Outcome Measures (PCOMs)
Access questionnaires assessing quality of life in this disease (English)
The documents contained in this website are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.